Key Market Segments
By Type
-
Human growth hormone
-
Erythropoietin
-
Monoclonal antibodies
-
Insulin
-
Granulocyte-Colony Stimulating Factor
By Application
-
Blood disorders
-
Oncology diseases
-
Chronic and autoimmune diseases
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of the Middle East
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Product Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Product Matrix which gives a detailed comparison of the product portfolio of each company
-
Geographic Analysis
-
Additional countries in any of the regions
-
Company Information
-
Detailed analysis and profiling of additional market players (Up to five)
Frequently Asked Questions
The U.S. Food and Drug Administration (FDA) has currently approved 41 biosimilars.
The Biosimilars Market size was valued at USD 29.51 Billion in 2023
The major key players are Dr Reddy’s Laboratories, Eli Lilly and Company, Pfizer Inc., Intas Pharmaceutical Ltd, Biocon Ltd, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Limited, Kashiv BioSciences, reliance life sciences and others
The Biosimilars market is to Hit USD 127.92 Billion by 2032.
The Biosimilars market is to grow at 17.7% Over the Forecast Period 2024-2032.